Full Press Release Details
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 5, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss financial results for the calendar year ended December 31, 2017, and provide important corporate updates.
BrainStorm's senior management team, including Chaim Lebovits, CEO, Ralph Kern, M.D., MHSc, COO & CMO, and Eyal Rubin, CFO, will host a conference call and webcast for the investment community on Thursday, March 8 at 8:30am Eastern.
Thursday, March 8, 2017 @ 8:30am Eastern Time
TOLL-FREE: 1-800-289-0438
TOLL/INTERNATIONAL: 1-323-794-2423
ISRAEL TOLL-FREE: 1809 212 883
Webcast link: https://goo.gl/tMC3zV
Replays, available through March 22, 2018
Replay Dial-In Numbers:
TOLL-FREE: 1-844-512-2921
TOLL/INTERNATIONAL: 1-412-317-6671
Replay Pin Number: 3071165
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: (646) 666-3188
LifeSci Advisors, LLC
SOURCE BrainStorm Cell Therapeutics Inc.
Related Links
21 %
more press release views with